Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation"

Transcription

1 Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist 215

2 Outline Immune Checkpoint and Combination Therapies Reporter Gene Bioassays: Design, Optimization and Qualification Co-inhibitory Bioassays Co-stimulatory Bioassays Combination Bioassays Custom Assay Services Summary

3 Immune Checkpoint Modulation antigen presenting cell T cell Co-stimulatory Receptors GITR 4-1BB (CD137) OX4 CD4 HVEM CD27 ICOS Co-inhibitory Receptors PD-1 CTLA-4 TIGIT LAG-3 BTLA Combination Targets PD-1 + TIGIT PD-1 + CTLA-4 PD-1 + LAG Mahoney, Rennert, Freeman et al. Nature Rev Drug Discovery (215) 3

4 Immune Checkpoint Therapy Releasing the Brakes, Hitting the Gas Strategy Blocking Ab for immune coinhibitory receptors (PD-1, CTLA-4, TIGIT, LAG3), release the brakes Agonist Ab for immune costimulatory receptors (GITR, OX4, CD27, CD137), hit the gas T effector cells are activated

5 Reporter Gene Bioassay: Design, Optimization, and Qualification 215.

6 Building Bioluminescent Reporter-Gene Bioassay Platform Performance capability: Reflect MOA; fast, highly sensitive, quantitative and reproducible; more stability-indicating than cell-free system Trainability/Transferability: Simple protocol, minimal effort needed for assay validation, analyst training and global transfer Standard equipment and reagents: Luminometer and luciferase reagents are available and commonly used in most cell biology labs

7 Reporter Gene Bioassay Development Workflow Phase 1: Assay design and POC study Phase 2: Stable cell line generation and characterization Phase 3: Make thaw-anduse cells Phase 4: Assay optimization, qualification, application MOA reflecting Choose relevant cell background Select appropriate reporter gene vector Transient transfection/proof of concept Assay specificity Endogenous or exogenous proteins Transfection FACS sorting Single cell cloning Clone morphology, growth rate & stability Functional performance Cell growth Cell freezing Cell storage Equivalent assay performance Assay optimization: single factor, DOE Assay qualification Assay application: 384-format, stability study, human serum tolerance

8 Immune Co-inhibitory Bioassays Case study: CTLA-4 Blockade Bioassay Other assays: PD-1, LAG3, TIGIT, BTLA 215.

9 General Assay Design for Co-Inhibitory Bioassay Co-inhibitory receptor ligand PD-L1/L2 CD8/CD86 CD155 MHC-II HVEM antigen presenting cell Ligand receptors TCR activator TCR T cell Inhibitory receptors RE Immune Co-inhibitory receptor Luciferase PD-1 CTLA-4 TIGIT LAG-3 BTLA 215. Ligand receptors aapc cells Co-stimulatory receptors (CD28, CD226) T Effector cells 9

10 Case Study: CTLA-4 Bioassay Development Stable Cell Generation and Characterization Transfection FACS Sorting Single Cell Cloning Cell line 1: CTLA-4 Effector cells CTLA-4 Luciferase reporter Receptor Expression Functional Tests Clone Stability Cell line 2: aapc/raji cells TCR activator protein

11 Case Study: CTLA-4 Bioassay Development Stable Cell Generation and Characterization Transfection FACS Sorting Single Cell Cloning Cell line 1: CTLA-4 Effector cells CTLA-4 Luciferase reporter Count Plot P5, ungated control anti-ctla Red Fluorescence (RED-HLog) Receptor Expression Functional Tests Clone Stability Cell line 2: aapc/raji cells TCR activator protein anti-tcr activator control

12 Case Study: CTLA-4 Bioassay Development Stable Cell Generation and Characterization Transfection FACS Sorting Single Cell Cloning Cell line 1: CTLA-4 Effector cells CTLA-4 Luciferase reporter Biolum inescence (RLU) passage# for CTLA-4 E ffe c to r c e lls P14 P26 P39 P53 P Log[ipilim um ab], ug/m l EC5 P P P P P Receptor Expression Functional Tests Clone Stability Cell line 2: aapc/raji cells TCR activator protein Biolum inescence (RLU) passage# for aapc/raji cells P13 P26 P44 P59 EC5 P P P P Log[ipilim um ab], ug/m l

13 Proposed Assay Protocol Prototype Assay Procedure: 1. Make assay buffer Buffer components 2. Plate CTLA-4 Effector cells Cell number/well 3. Add anti-ctla-4 Ab 4. Plate aapc/raji cells Cell number/well 5. Induction Induction time 6. Add Bio-Glo Reagent, read plates Add anti- CTLA-4 Ab plate CTLA-4 Effector Cells Effector Cell number Assay buffer components aapc Cell number Plate aapc/raji Cells Add/Read Induction Induction time Add Bio-Glo Reagent Measure Luminescence

14 Assay Optimization Cell Plating Density & E:T Ratio Two Factors 1. # Effector Cells 1K 15K 2. # aapc Cells 5K 1K 15K 2K Output 1. Uninduced RLU 2. EC 5 3. Fold induction Bioluminescence (RLU) Log[ipilimumab], ug/ml E : T ratio 1K : 5K 1K : 1K 1K : 15K 1K : 2K 15K : 5K 15K : 1K 15K : 15K 15K : 2K 17 hour induction 1% FBS in assay buffer Test factors/parameters Outputs run Effector Cell# aapc Cell# uninduced RLU EC 5, ug/ml Fold induction 1 1K 5K K 1K K 15K K 2K K 5K K 1K K 15K K 2K

15 DOE for Assay Optimization Two factors: Induction Time & Assay Buffer Two Factors 1. Induction time: 6 hours 16 hours 24 hours 2. % FBS in assay buffer: 1%- 1% FBS Output 1. Uninduced RLU 2. EC 5 3. Fold induction E: T= 1K : 2K Bioluminescence (RLU) induction time/assay buffer 6 hour/1% FBS 6 hour/5%fbs 6hour/2% FBS 6hour/1% FBS 6 hours 1 16 hours 23 hours Bioluminescence (RLU) 3 induction time/assay buffer 16 hour/1% FBS 16 hour/1% FBS 2 23 hour/1% FBS 23 hour/1% FBS Log[ipilimumab], ug/ml Log[ipilimuab], ug/ml Test factors/parameters Output run Induction time Assay Buffer uninduced RLU EC 5, ug/ml Fold induction 1 6 hour 1% FBS hour 2% FBS hour 5% FBS hour 1% FBS hour 1% FBS hour 1% FBS hour 1% FBS hour 1% FBS

16 DOE for Assay Optimization Two Factors: Induction Time & # aapc/raji Cells Two factors 1. Induction time: 6 hours 16 hours 2. # aapc/raji cells/well: 1K 5K 2K Output 1. Uninduced RLU 2. EC 5 3. Fold induction Bioluminescence (RLU) aapc/raji cells/well 1K 5K 2K 6 hours Log[ipilimumab], ug/ml Bioluminescence (RLU) k effector cells, 1% FBS in assay buffer aa P C /R aji cells/w ell 1K 5K 2K 16 hours Log [ipilimumab], (ug/ml) Test factors/parameters Outputs run Induction time aapc/raji cells/well uninduced RLU EC 5, ug/ml Fold induction 1 6 hour 1K hour 5K hour 2K hour 1K hour 5K hour 2K

17 Final Assay Protocol Assay Procedure: 1. Make assay buffer containing 1% FBS 2. Plate CTLA-4 Effector cells at 1K/well 3. Add anti-ctla-4 Ab 4. Plate aapc/raji cells at 5K/well 5. Induction for 6 hours or 16 hours depending on plate reader and Ab binding kinetics 6. Add Bio-Glo Reagent, read plates Add anti- CTLA-4 Ab Plate CTLA-4 Effector Cells Plate aapc/raji Cells Add/Read Induction Add Bio-Glo Reagent Features: No need for primary cells Simple, homogenous Sensitive, highly reproducible Short assay time Measure Luminescence

18 CTLA-4 Bioassay Qualification Qualification Parameters: Specificity Accuracy Precision: Repeatability (intra-assay precision) Intermediate precision (day to day, analyst to analyst) Reproducibility (lab to lab) Linearity Range Robustness - ICH Guideline Q2 [R1] - USP <133> Biological Assay Validation Bioluminescence (RLU) Assay Qualification Design: Two analysts Three days Four plates per day 1. 1% vs 5% 2. 1% vs 7% 3. 1% vs 13% 4. 1% vs 15% 5% 7% 1% 13% 15% Relative Potency Log 1 [ipilim um ab], ug/m l

19 Precision, Accuracy and Linearity Parameter Results % Expected Relative Potency % Recovery Accuracy Repeatability (%CV) 1% (Reference) 6.66 Intermediate Precision (% CV) 1.22 Linearity (r 2 ).991 Linearity (y = mx + b) y = x Measured Relative Potency (%) Linearity Y=1.175X R2= Expected Relative Potency (%) A 5 15% theoretical potency series of ipilimumab was analyzed in triplicate in three independent experiments performed on three days by two analysts Data were analyzed and relative potencies calculated after parallelism determination using JMP software Data were generated using thaw-and-use cells

20 Assay Specificity anti-ctla-4, ipilimumab, human IgG1 Bioluminescence (RLU) anti-pd-1, nivolumab, human IgG4 anti-tigit, mouse IgG1 anti-her2, trastuzumab, human IgG Log 1 [test antibody], ug/ml

21 Assay is Stability-Indicating Heat treatment Bioluminescence (RLU) o C Control 65 o C 8hr 65 o C 16hr 65 o C 24hr EC 5, µg/ml 4 o C Control o C 8h o C 16h NA 65 o C 24h NA Log 1 [ipilim um ab], ug/m l

22 Combine with ADCC Reporter Bioassay for Fc Effector Function of anti-ctla-4 Antibody CTLA-4 CTLA-4 Effector FcγRIIIa Cells serve as Target anti-ctla4 cells Y anti-ctla-4 Ab ipilimumab, human IgG1 ADCC Effector Cells = NFAT-RE-luc Glo Assay specifics: Effector cells: ADCC Bioassay Effector Cells, V Variant Target cells: CTLA-4 Effector Cells Bioluminescence (RLU) research grade anti-ctla-4 Ab: Control Ab, human IgG1 Ab 2, human IgG4 Ab 3, mouse IgG1 E:T ratio: 6:1 6 hour induction Log 1 [anti-ctla -4 Ab], ug/m l

23 Immune Co-inhibitory Bioassay Portfolio PD-1/PD-L1/L2 Blockade Assay A Pair of PD-1 Blockade Bioassays Specific for Individual PD-1 Ligand Interaction Brief protocol: 1. Plate aapc cells 2. Add blocking Ab 3. Plate Effector cells 4. Induction; add Bio-Glo Reagent and read plates Bioluminescence (RLU) A. PD-1/PD-L1 Bioassay B. PD-1/PD-L2 Bioassay PD-1 Ab PD-L1 Ab PD-L2 Ab Log [research grade antibody], g/ml Bioluminescence (RLU) PD-1 Ab PD-L1 Ab PD-L2 Ab Log [research grade antibody], g/ml

24 Immune Co-inhibitory Bioassay Portfolio (cont.) Brief protocol: 1. Plate aapc cells 2. Add blocking Ab 3. Plate Effector cells 4. Induction; add Bio-Glo Reagent and read plates TIGIT A. TIGIT/CD155 Bioassay B. LAG-3/MHC-II Bioassay C.BTLA/HVEM Bioassay Bioluminescence (RLU) A nti- TIG IT A nti- PD -1 Biolum inescence (RLU) Biolum inescence (RLU) Log[test antibody], µ g/ml Log[anti-LAG-3] µ g /m l L o g [a n ti-h V E M ], g /m l

25 Immune Co-Stimulatory Bioassays Case study: OX4 Bioassays Other bioassays: GITR, 4-1BB, CD4, HVEM, CD

26 Immune Co-stimulatory Receptors Expressed on T cells, B cells, NK cells and antigen presenting cells I. List of immune co-stimulatory receptors Belong to the TNFR superfamily; activate NF-κB pathway II. Immune co-stimulatory receptor signaling Play important roles in the amplification of T cell-mediated immune responses 215. Chen and Flies, Nature Reviews Immunology 13 (213) 26

27 General Assay Design for Co-stimulatory Bioassays Ligand (Soluble or cell bound) Agonist Ab Co-stimulatory Receptors: OX4 GITR 4-1BB CD4 HVEM CD27 RE Co-stimulatory Receptor Luciferase Co-stimulatory Receptor-expressing Effector Cell

28 Case study: OX4 Bioassay Development Cell Line Stability and Characterization Transfection OX4 Effector cells 1. OX4 2. Luciferase reporter FACS Sorting Single Clone Selection Receptor Expression & Functional Tests Clone Stability

29 Case study: OX4 Bioassay Development Cell Line Stability and Characterization Transfection FACS Sorting Single Clone Selection Receptor Expression & Functional Tests Clone Stability Count OX4 Effector cells 1. OX4 2. Luciferase reporter Plot P3, gated on P1.R1 control anti-ox4 R3 R Yellow Fluorescence (YEL-HLog)

30 Case study: OX4 Bioassay Development Cell Line Stability and Characterization Transfection OX4 Effector cells 1. OX4 2. Luciferase reporter FACS Sorting Single Clone Selection 12 p22 Receptor Expression & Functional Tests Fold of Induction 8 4 p4 p53 Clone Stability Log[OX4L], ng/m l

31 Proposed Assay Protocol Prototype Assay Procedure: 1. Make assay buffer Buffer components 2. Plate OX4 Effector cells Cell number/well 3. Add OX4L or anti-ox4 Ab 4. Induction Induction time 5. Add Bio-Glo Reagent, read plates Plate OX4 Effector Cells Add OX4L or anti-ox4 Ab or Add/Read Induction Induction time Add Bio-Glo Reagent Cell number Assay buffer components Measure Luminescence

32 Assay Optimization FBS in Assay Buffer Thaw-and-Use Cells Fresh-from-Culture Cells Biolum inescence (RLU) 3 1% FBS 5% FBS 2 1% FBS Log[OX4L], g/m l Biolum inescence (RLU) 4 1% FBS 5% FBS 3 1% FBS Log[OX4L], g/m l EC5 1% FBS 2.555e-8 5% FBS 2.89e-8 1%FBS 2.86e-8 EC5 1% FBS ~ 2.437e-24 5%FBS 1.981e-8 1% FBS 1.49e-8 Summary: 5% FBS in assay buffer is optimal for assays with thaw-and-use cells and fresh cells from culture

33 Assay Optimization Induction Time & Cell Number Induction Time Cell Number Biolum inescence (RLU) 25 3hr 4hr 2 5hr 6hr 15 7hr 24hr Log[O X4L], ng/m L Biolum inescence (RLU) 3 5K 1k 2 15k Log[O X4L], ng/m L Induction time EC 5, ng/ml Fold Cell#/well EC 5, ng/ml Fold 3 hour K hour hour hour K K hour hour NA ~

34 Final Assay Protocol Assay Procedure: 1. Make assay buffer containing 5% FBS 2. Plate OX4 Effector cells at 5K/well 3. Add OX4L or anti-ox4 Ab 4. Induction for 5 hours 5. Add Bio-Glo Reagent, read plates Plate OX4 Effector Cells Add OX4L or anti-ox4 Ab or Add/Read Induction Add Bio-Glo Reagent Measure Luminescence

35 OX4 Bioassay Response to soluble ligand and agonist antibody OX4 Ligand OX4 Agonist Antibody Biolum inescence (RLU) EC5=8.1 ng/ml Fold Induction= Biolum inescence (RLU) EC5 = 14.7 ng/ml Fold Induction= Log[OX4L], ng/m l Log[anti-OX4 Ab], ng/m l

36 GITR Bioassay and 4-1BB (CD137) Bioassay Brief protocol: 1. Plate Effector cells 2. Add ligand or agonist Ab 3. Induction 4. Add Bio-Glo Reagent and read plates Biolum inescence (RLU) Biolum inescence (RLU) GITR Ligand Crosslinked G ITRL EC5=29.1 ng/ml Fold Induction=33 G IT R L EC5=9.1 ng/ml Fold Induction= GITR Agonist Antibody EC5=185 ng/ml Fold Induction=3 Log[GITRL], ng/m l Log[anti-GITR Ab], ng/m l Biolum inescence (RLU) Biolum inescence (RLU) BB Ligand crosslinked 4-1BBL EC5=12.5 ng/ml Fold Induction= B B L EC5=17.9 ng/ml Fold Induction= Log[4-1BBL], ng/m l 4-1BB Agonist Antibody EC5=32.9 ng/ml Fold Induction= Log[anti-4-1BB Ab], ng/m l

37 CD27 Bioassay CD27 activation by CD7 expressing cells Block CD27/CD7 interaction by anti-cd27 antibody Bioluminescence (RLU) Biolum inescence (RLU) log cells/well (CHO-CD7) lo g [a n ti-c D 2 7 ], g /m l Brief protocol: 1. Plate CD7 expressing cells 2. Add CD27 Effector cells 3. Induction; add Bio-Glo Reagent and read plates Brief protocol: 1. Plate CD7 expressing cells 2. Add CD27 Effector cells 3. Add anti-cd27 blocking Ab 4. Induction; add Bio-Glo Reagent and read plates

38 HVEM/LIGHT Bioassay HVEM activation by soluble LIGHT Block HVEM/LIGHT interaction by anti-hvem antibody Biolum inescence (RLU) L IG H T lig a n d a n ti-h V E M b lo c k in g A b Log [test agents], g/m L Bioluminescence (RLU) HVEM activation by LIGHT-expressing cells log [LIGHT Target Cells/well] Brief protocol: 1. Plate HVEM Effector cells 2. Add soluble LIGHT (left, blue line), or LIGHT expressing cells (right) 3. Add anti-hvem antibody (left, red line) 4. Induction; add Bio-Glo Reagent and read plates

39 Determining Antibody Specificity HVEM/LIGHT vs BTLA/HVEM Bioassays HVEM/LIGHT Bioassay BTLA/HVEM Blockade Bioassay Biolum inescence (RLU) Ab 1, m onoclonal Ab Ab 2, polyclonal Ab Biolum inescence (RLU) Ab 1, m onoclonal Ab Ab 2, polyclonal Ab L o g [a n ti-h V E M ], g /m l L o g [a n ti-h V E M ], g /m l EC5 Ab 1, monoclonal Ab 2.934e-8 Ab 2, polyclonal Ab 2.64e-8 EC5 Ab 2, polyclonal Ab 3.967e

40 CD4 Bioassay CD4 activation by CD4L Blocking CD4/CD4L interaction with anti-cd4l antibody CD4 activation by CD4 Agonist Ab Biolum inescence (RLU) CD154 (CD4L) anti-cd4l blocking Ab Biolum inescence (RLU) L o g [te s t a g e n ts ], g /m l L o g [a n ti-c D 4 ], g /m l Brief protocol: 1. Plate CD4 Effector cells 2. Add soluble CD4 ligand (left, blue line), or CD4 agonist Ab (right) 3. Add anti-cd4l antibody (left, red line) 4. Induction; add Bio-Glo Reagent and read plates

41 Crosslinking of Agonist Antibody by FcγRIIb Promotes Downstream Signaling Assay Design FcγRIIb expressing cells Wilson et al. Cancer Cell (211) Crosslinking of antibodies bound to target by FcγR-expressing cells can promote receptor clustering and increase downstream signaling FcγRIIb crosslinking is important for anti-tnfr receptor antibodies (anti-cd4, anti-trail) Antibodies can be engineered for higher or lower FcgRIIb binding anti-cd4 Agonist Ab Luc CD4 Effector Cells

42 CD4 Bioassay can be used to Detect FcγRIIb-dependent Ab Bioactivities Ab characterization in primary cells: same Fab, different Fc CD23 B Cell FcγR Isotype upregulation Proliferation Dependency No1 + + No higg2 No2 + + Yes migg1 FcγRIIb-independent FcγRIIb-dependent 6 T e s t A b 1 (+ C H O w.t.) 6 T e s t A b 2 (+ C H O w.t.) Fold Induction 4 2 Test Ab 1 (+ CHO Fcγ R IIb ) Fold Induction 4 2 Test Ab 2 (+ CHO Fcγ R IIb ) lo g [te s t A b ], g /m l lo g [te s t A b ], g /m l

43 Immune Combination Bioassays PD-1+TIGIT PD-1+LAG3 215.

44 General Assay Design for Dual-inhibitory Combination Bioassays Two co-inhibitory receptor ligands PD-L1+CD155 PD-L1+MHC-II Two Ligand receptors Two immune co-inhibitory receptors Two Inhibitory receptors PD-1+TIGIT PD-1+LAG3 TCR activator TCR RE Luciferase Ligand receptors aapc cells Co-stimulatory receptors (CD28, CD226) T Effector cells

45 Combination Bioassays PD-1+TIGIT, PD-1+LAG3 A. PD-1+TIGIT Combo Bioassay B. PD-1+LAG-3 Combo Bioassay Bioluminescence (RLU) anti-pd -1 anti-tig IT anti-pd-1 + anti-tig IT Log[test antibody], µ g/m l Biolum inescence (RLU) a n ti-p D an ti-l A G -3 a n ti-p D -1 + an ti-l A G Log[test antibody], µ g /m l

46 Promega Bioassay Portfolio Fc Functions Fc Effector Bioassays FcγRIIIa (V/F) FcγRIIa (H/R) FcγRI madcc Immune Target Bioassays Immune Checkpoint Bioassays Co-inhibitory: PD-1, CTLA-4, TIGIT, LAG-3, BTLA Co-stimulatory: OX4, GITR, 4-1BB, CD4, HVEM, CD27 Combination Bioassays Target Based Immunotherapy T Cell Activation Bioassays (BiTE, CAR) Other Biologics Cytokine Bioassays IL-2, IL-6, IL-12/23 EGF, VEGF IFNα, IFNβ, IFNγ

47 Promega Custom Bioassays Promega Custom Assay Services (CAS): Builds custom bioassays to meet your specific needs Projects are milestone based and payments are made upon completion of each milestone Example Project Outline: Feasibility study Stable cell line generation Assay optimization Assay qualification Transient transfection Proof of concept Assay reproducibility Stable pool generation Single clone selection Cell number/well Agonist concentration Luciferase induction time Antibody concentration Accuracy Precision Specificity Linearity

48 Reporter Gene Bioassays Offer A MOA-based functional bioassay for biologics drug development Consistent and reliable measure of biologics potency and stability o Demonstrated precision, accuracy, reproducibility and robustness o Simple thaw-and-use format o Kits include all required reagents in a standardized format Easy-to-implement o Rapid and convenient workflow o Compatible with 96- and 384-well assay formats Building blocks for combination immunotherapies

49 Thank You! Jey Cheng, PhD R&D Group Leader, Bioassay Development Gopal Krishnan PhD Global Product Manager Vanessa Ott, PhD Global Strategic Marketing Manager Custom Assay Services

Reporter Gene Immunotherapy Bioassays

Reporter Gene Immunotherapy Bioassays Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation

More information

Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways

Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Shihua Lin, PhD. Senior Scientist Analytical Biotechnology Development, MedImmune

More information

ADCC Reporter Bioassays - V and F Variants:

ADCC Reporter Bioassays - V and F Variants: ADCC Reporter Bioassays - V and F Variants: Novel, Bioluminescent Cell-Based Assays for Quantifying Fc Effector Function of Antibodies Promega Corporation April 2014 Rev 01 Topics Presented Introduction

More information

VEGF Bioassay Instructions for use of Product GA2001 and GA2005

VEGF Bioassay Instructions for use of Product GA2001 and GA2005 TECHNICAL MANUAL VEGF Bioassay Instructions for use of Product GA21 and GA25 9/18 TM544 VEGF Bioassay All technical literature is available at: www.promega.com/protocols/ Visit the web site to verify that

More information

T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655.

T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655. TECHNICAL MANUAL T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655. 11/16 TM492 T Cell Activation Bioassay (IL-2) All technical literature is available at: www.promega.com/protocols/

More information

Controlling cell-based bioassay performance through controlled preparation of bioassayready

Controlling cell-based bioassay performance through controlled preparation of bioassayready Controlling cell-based bioassay performance through controlled preparation of bioassayready cells Teresa Surowy September 2013 Promega Corporation Introduction The importance of cell-based bioassays and

More information

Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538

Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Background: TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory

More information

T Cell Activation, Costimulation and Regulation

T Cell Activation, Costimulation and Regulation 1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family

More information

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D. Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

Bioassays for Quality Control of Cell & Gene Therapy Products

Bioassays for Quality Control of Cell & Gene Therapy Products Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen

More information

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective CASSS Bioassays May 09, 2017 Tara Stauffer 1 Overview Introduction: Cell-based bioassays in IO product development Immuno-Oncology (IO)

More information

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ T lymphocytes used in all NK activation and cytotoxicity

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint APPLICATION NOTE AlphaLISA Technology Authors: Matthew Marunde Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint Introduction

More information

Immune Checkpoint Proteins

Immune Checkpoint Proteins Immune Checkpoint Proteins www.acrobiosystems.com Content I. Introduction II. Biotinylated Immune Checkpoint Proteins III. PD1:PDL1 Inhibitor Screening Assay Kit IV. HPLC-Verified Checkpoint Proteins V.

More information

C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.

C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine. www.adipogen.com 2014 fusion Proteins Laboratories The Experts for High Quality Fusion Proteins NEW NEW Butyrophilin-like 2 [BTNL2] Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology

More information

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535 Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535 Product Description Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive

More information

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30

More information

Identification of novel immune regulators of tumor growth using highthroughput

Identification of novel immune regulators of tumor growth using highthroughput Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein

More information

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1)

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Sujan Badal, MS2; Zachary B. Davis, PhD; Jeffrey Miller, MD Department of Medicine, Division of Hematology, Oncology, and Transplantation

More information

Your Partner in Proteomics. Reporter System Luciferase Reporter Stable Cell Lines One-Step Luc Assay Kit Stable Cell Lines.

Your Partner in Proteomics. Reporter System Luciferase Reporter Stable Cell Lines One-Step Luc Assay Kit Stable Cell Lines. Reporter System Luciferase Reporter Stable Cell Lines One-Step Luc Assay Kit Stable Cell Lines www.abeomics.com Reporter Cell Lines Reporter cell lines are used for cell-based assays for screening of drugs/compounds

More information

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535 Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535 Product Description Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

Data Sheet. NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621

Data Sheet. NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621 Data Sheet NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621 Background The nuclear factor of activator T cells (NFAT) family of transcription factors plays an important role in immune response. T

More information

Data Sheet NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621

Data Sheet NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621 Data Sheet NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621 Background The nuclear factor of activator T cells (NFAT) family of transcription factors plays an important role in immune response. T

More information

A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue

A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue Soner Altiok, MD, PhD Chief Scientific Officer Nilogen Oncosystems Tampa, Florida - Nilogen Oncosystems,

More information

Lumino Firefly Luciferase Assay

Lumino Firefly Luciferase Assay G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name Lumino Firefly Luciferase Assay (Cat. # 786 1267, 786 1268) think proteins! think G-Biosciences

More information

Supplemental Materials

Supplemental Materials Supplemental Materials Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability Qi Wang 1, Jianwei He 1, Dallas B. Flies 2, Liqun Luo

More information

Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated

Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated 1 Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated (U) EGFR TL mice (n=7), Kras mice (n=7), PD-1 blockade

More information

Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 60481

Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 60481 642 Cornerstone Court W, Ste B Tel: 1.858.829.382 Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 6481 Description Human IL-2 reporter construct is stably integrated into the genome

More information

Immunology. Antibodies for immunology research

Immunology. Antibodies for immunology research Immunology Antibodies for immunology research antibodies for immunology research BP0169 BP0003-1 BP0004-1 BP0061 CD4 + T cells Control LOB12.3 Relative Cell Number CD4 (55 kda) CD8α (35 kda) CD8α (35 kda)

More information

FOXO Reporter Kit PI3K/AKT Pathway Cat. #60643

FOXO Reporter Kit PI3K/AKT Pathway Cat. #60643 Data Sheet FOXO Reporter Kit PI3K/AKT Pathway Cat. #60643 Background The PI3K/AKT signaling pathway is essential for cell growth and survival. Disruption of this pathway or its regulation has been linked

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin

Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Abhi Saharia, Ph. D. Director of Marketing Bioassays in Biologics Development Research

More information

Preclinical investigation of the promise and challenges of agonistic anti-gitr antibody therapy. Amy Beebe Merck Research Laboratory March 16, 2017

Preclinical investigation of the promise and challenges of agonistic anti-gitr antibody therapy. Amy Beebe Merck Research Laboratory March 16, 2017 Preclinical investigation of the promise and challenges of agonistic anti-gitr antibody therapy Amy Beebe Merck Research Laboratory March 16, 2017 Rationale for anti-gitr agonist in cancer GITR is a co-stimulatory

More information

Bioactivity Assays: Putting the Puzzle Together

Bioactivity Assays: Putting the Puzzle Together Bioactivity Assays: Putting the Puzzle Together Dr. Ulrike Herbrand Department for Biosafety & Bioassay Services Charles River Biologics Testing Solutions Outline General Remarks MoA reflecting bioassays

More information

Pre-made Reporter Lentivirus for MAPK/ERK Signal Pathway

Pre-made Reporter Lentivirus for MAPK/ERK Signal Pathway Pre-made Reporter for MAPK/ERK Signal Pathway Cat# Product Name Amounts LVP957-P or: LVP957-P-PBS SRE-GFP (Puro) LVP958-P or: LVP958-P-PBS SRE-RFP (Puro) LVP959-P or: LVP959-P-PBS SRE-Luc (Puro) LVP960-P

More information

QS S Assist KINASE_ADP-Glo TM Kit

QS S Assist KINASE_ADP-Glo TM Kit QS S Assist KINASE_ADP-Glo TM Kit Description KINASE ADP-Glo TM kit is designed for use in biochemical kinase assays based on a Luminescent ADP Detection Assay (ADP-Glo TM ). The kit includes human kinase,

More information

Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity

Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity ADCC Effector Cells In Antibody Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity M. Jules Mattes Potential ADCC effector cells and their Fcγ receptors Cell type Fcγ receptors

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.

More information

Plate-Based Assay Methods for the Assessment of Cellular Health

Plate-Based Assay Methods for the Assessment of Cellular Health Plate-Based Assay Methods for the Assessment of Cellular Health Andrew L. Niles, Senior Research Scientist 2012, Promega Corporation. Biological Outcomes in Cell Culture Treatment -Small molecule -Bio-molecule

More information

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Disclosure Research Funding from BMS. Learning Objectives -Define belatacept-resistant rejection

More information

AlphaScreen TNFα Binding Assay Kit: A Homogeneous, Sensitive and High-Throughput Assay for Screening TNFα Receptors

AlphaScreen TNFα Binding Assay Kit: A Homogeneous, Sensitive and High-Throughput Assay for Screening TNFα Receptors AlphaScreen TNFα Binding Assay Kit: A Homogeneous, Sensitive and High-Throughput Assay for Screening TNFα Receptors Bouchard N., Legault M. and Wenham D. PerkinElmer BioSignal, 1744 William, suite 3, Montréal,

More information

PD-L1, PD-1, LAG-3, CD40, CD86, CD27, CD70

PD-L1, PD-1, LAG-3, CD40, CD86, CD27, CD70 /, Vol. 7, No. 47 T-cell responses against CD19 + pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts

More information

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017 GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics

More information

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009 T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells

More information

Cancer immunotherapy with oncolytic viruses: more than just lysis

Cancer immunotherapy with oncolytic viruses: more than just lysis Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank

More information

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

DISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d

DISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,

More information

Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).

Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1). Supplementary Figure Legends Supplemental Figure : Naïve T cells express Siglec-G. Splenocytes were isolated from WT B or Siglec-G -/- animals that have not been transplanted (n= per group) and analyzed

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018 NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

ASTARTE IN ACTION. Using a Recall Antigen Assay as a Tool for Understanding Immunity CASE STUDY

ASTARTE IN ACTION. Using a Recall Antigen Assay as a Tool for Understanding Immunity CASE STUDY ASTARTE IN ACTION Using a Recall Antigen Assay as a Tool for Understanding Immunity CASE STUDY Introduction While there is no industry-accepted protocol for measuring the functionality of peripheral blood

More information

Data Sheet. CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions

Data Sheet. CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions Data Sheet CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit Catalog # 72062 Size: 96 reactions BACKGROUND: The activation of naïve T cells requires two signals; the specific T cell receptor recognition

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

Novel Approaches to CAR-T Cell Platform

Novel Approaches to CAR-T Cell Platform Novel Approaches to CAR-T Cell Platform Vita Golubovskaya, Ph.D. Director, R&D Promab Biotechnologies 3 rd CAR-TCR Summit 2017 S E P T E M B E R 5-7 B O S T O N Novel Approaches To CAR-T Cell Platform

More information

Pre-made Reporter Lentivirus for JAK-STAT Signaling Pathway

Pre-made Reporter Lentivirus for JAK-STAT Signaling Pathway Pre-made Reporter for JAK-STAT Signaling Pathway Cat# Product Name Amounts LVP937-P or: LVP937-P-PBS ISRE-GFP (Puro) LVP938-P or: LVP938-P-PBS ISRE-RFP (Puro) LVP939-P or: LVP939-P-PBS ISRE-Luc (Puro)

More information

Pre-made Reporter Lentivirus for NF-κB Signal Pathway

Pre-made Reporter Lentivirus for NF-κB Signal Pathway Pre-made Reporter for NF-κB Signal Pathway Cat# Product Name Amounts LVP965-P or: LVP965-P-PBS NFKB-GFP (Puro) LVP966-P or: LVP966-P-PBS NFKB-RFP (Puro) LVP967-P or: LVP967-P-PBS NFKB-Luc (Puro) LVP968-P

More information

Heat Biologics. Corporate Presentation March 9, 2018

Heat Biologics. Corporate Presentation March 9, 2018 Heat Biologics Corporate Presentation March 9, 2018 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements within the meaning of the Private

More information

Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis

Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Vincent Laufer Rheumatology JC October 17 Disclosures NIH 2

More information

Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors

Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors Tibor Keler, PhD Chief Scientific Officer Enhancing immunity with immune modulating

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

EXOTESTTM. ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids

EXOTESTTM. ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids DATA SHEET EXOTESTTM ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids INTRODUCTION Exosomes are small endosome-derived lipid nanoparticles

More information

AlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director

AlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director AlphaScreen : A Straightforward and Powerful Alternative to ELISA Martina Bielefeld-Sévigny Ph.D., R&D Director Overview AlphaScreen - an alternative to ELISA Why an alternative to ELISA? Assay principle

More information

Mouse serum Insulin 200 tests

Mouse serum Insulin 200 tests Headquarters & Europe Office Cisbio Bioassays Phone: +33 (0)4 66 79 67 05 Fax: +33 (0)4 66 79 19 20 bioassays@cisbio.com cisbio_dd_pi_62in3pef-2µl USA Office Cisbio US, Inc. Phone: +1 888 963 4567 Fax:

More information

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL

More information

The chronic inflammatory nature of atherosclerotic disease

The chronic inflammatory nature of atherosclerotic disease T-Cell Costimulation and Coinhibition in Atherosclerosis Israel Gotsman, Arlene H. Sharpe, Andrew H. Lichtman Abstract Evidence from many human and rodent studies has established that T lymphocytes enhance

More information

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy

More information

CANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL

CANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL FARMAFORUM 2015 FACULTAD FARMACIA CANCER IMMUNOTHERAPY Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL The immune response to tumors Oncogenic event The immune

More information

Bead Based Assays for Cytokine Detection

Bead Based Assays for Cytokine Detection Bead Based Assays for Cytokine Detection September 27, 2014 6 th EFIS-EJI South East European Immunology School SEEIS 2014 Timisoara, Romania The Cells of the Immune System The Immune Reaction (Th2) (Th1)

More information

Emerging Tissue and Serum Markers

Emerging Tissue and Serum Markers Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice

More information

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed

More information

Supplementary Figure 1 IL-27 IL

Supplementary Figure 1 IL-27 IL Tim-3 Supplementary Figure 1 Tc0 49.5 0.6 Tc1 63.5 0.84 Un 49.8 0.16 35.5 0.16 10 4 61.2 5.53 10 3 64.5 5.66 10 2 10 1 10 0 31 2.22 10 0 10 1 10 2 10 3 10 4 IL-10 28.2 1.69 IL-27 Supplementary Figure 1.

More information

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone

More information

Nobel Prize in Physiology or Medicine 2018

Nobel Prize in Physiology or Medicine 2018 Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan

More information

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies After decades of investigation establishing principles in

More information

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge,

TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge, TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge, 26.06.2018 Dr. Juergen Gamer, VP Business Development 1 Overview 1 Clinical stage immuno-oncology company focusing

More information

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Next generation of immune checkpoint therapy in cancer: new developments and challenges Marin-Acevedo et al. Journal of Hematology & Oncology (2018) 11:39 https://doi.org/10.1186/s13045-018-0582-8 REVIEW Next generation of immune checkpoint therapy in cancer: new developments and challenges

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Personalized Cancer Neoantigen Vaccines

Personalized Cancer Neoantigen Vaccines Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,

More information

Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay

Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay pplication Note Immunotherapy Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RN in situ hybridization RNscope assay Ming-Xiao He, Na Li, Courtney nderson,

More information

AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification

AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification BD AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification Overview of BD AbSeq antibody-oligonucleotide conjugates. High-throughput

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline 1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for

More information

Validation & Assay Performance Summary

Validation & Assay Performance Summary Validation & Assay Performance Summary LanthaScreen IGF-1R GripTite Cells Cat. no. K1834 Modification Detected: Phosphorylation of Multiple Tyr Residues on IGF-1R LanthaScreen Cellular Assay Validation

More information

Taking the brakes off the immune system: modelling effects in non-clinical safety studies

Taking the brakes off the immune system: modelling effects in non-clinical safety studies Taking the brakes off the immune system: modelling effects in non-clinical safety studies Dr Kirsty Harper, Head of Biologics, UK 2018 Envigo 1 envigo.com Overview + Introduction to the immune system +

More information

New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine

New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine New technologies for studying human immunity Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine New strategies: Human immunology is ideal for a systems approach We have

More information

PERIOSTIN ELISA CONTENTS

PERIOSTIN ELISA CONTENTS PERIOSTIN ELISA for the quantitative determination of Periostin in human serum, EDTA plasma, heparin plasma, and citrate plasma Cat. No. BI-20433. 12 x 8 tests CONTENTS ASSAY CHARACTERISTICS Summary...

More information

Combination Therapies Based on PD-1 or PD-L1 Blockade

Combination Therapies Based on PD-1 or PD-L1 Blockade Combination Therapies Based on PD-1 or PD-L1 Blockade Melanoma Bridge Naples, Italy December 4, 214 Mario Sznol- Yale University (in Absentia) Summary of Anti-PD-1/PD-L1 Activity in Metastatic Melanoma

More information

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints Supplementary Figure 1 Using DNA barcode-labeled MHC multimers to generate TCR fingerprints (a) Schematic overview of the workflow behind a TCR fingerprint. Each peptide position of the original peptide

More information

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation

More information

Immune Checkpoint Blockade against Malignancy. Blocking Self-inflicted Inhibitions?

Immune Checkpoint Blockade against Malignancy. Blocking Self-inflicted Inhibitions? Immune Checkpoint Blockade against Malignancy Blocking Self-inflicted Inhibitions? IGNORANT T CELL ANERGIC T CELL APOPTOTIC T CELL (DELETED) Insufficient antigen/ lack of co-stimulatory signals Unsuccessful

More information